Filing Flows › Editas Medicine (EDIT) › Q1 2025
Editas Medicine (EDIT) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 12, 2025
Editas Medicine (EDIT) reported revenue of $4.7M for the first quarter 2025 (Q1 2025), +310% from a year earlier and -85% from the quarter before.
Editas Medicine, Q1 2025: revenue $4.7M (+310% year over year), net loss $76.1M, operating cash flow −$47.8M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $4.7M | -85% | +310% |
| Operating profit | −$76.2M | — | — |
| Net earnings | −$76.1M | — | — |
| Operating cash flow | −$47.8M | — | — |
What changed
Revenue was $4.7M in Q1 2025, up 310% year over year and down 85% from the previous quarter.
Operating costs exceeded revenue by $76.2M, an operating margin of -1635.1%. Total costs grew 19% against revenue growth of 310%. The quarter ended with a net loss of $76.1M, wider than the previous quarter's $45.4M loss.
Operating cash flow was −$47.8M. Non-cash charges added back $1.9M of depreciation and $3.0M of share-based compensation. Working capital and other items added $23.4M. Capital expenditures of $114K exceeded it, leaving free cash flow of −$47.9M.
Questions
What was Editas Medicine's revenue in the first quarter 2025?
Editas Medicine (EDIT) reported revenue of $4.7M for the first quarter 2025 (Q1 2025), +310% from a year earlier and -85% from the quarter before.
Source: Editas Medicine 10-Q on SEC EDGAR.